X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CF-370 will be the first engineered lysin therapeutic targeting Gram-negative pathogens to enter a human clinical trial for hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia.
Lead Product(s): CF-370
Therapeutic Area: Infections and Infectious Diseases Product Name: CF-370
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 16, 2023
Details:
The IND application supports a proposed indication for its intravenous (IV) antibacterial agent, CF-370, for treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP).
Lead Product(s): CF-370
Therapeutic Area: Infections and Infectious Diseases Product Name: CF-370
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2023
Details:
The company intends to use the net proceeds to support ongoing enrollment of patients in the Phase 1b/2 clinical study of intra-articular CF-301 (exebacase), a first-in-class direct lytic agent, for the treatment of chronic prosthetic joint infections of the knee.
Lead Product(s): Exebacase
Therapeutic Area: Infections and Infectious Diseases Product Name: CF-301
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $9.6 million Upfront Cash: Undisclosed
Deal Type: Financing June 27, 2023
Details:
CF-301 (exebacase) is a lysin with potent activity against staphylococcus aureus ("Staph aureus"). It has the potential to be the first-in-class of a new treatment for chronic prosthetic joint infections of the knee.
Lead Product(s): Exebacase
Therapeutic Area: Infections and Infectious Diseases Product Name: CF-301
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2023
Details:
CF-301 (exebacase) is a lysin with potent activity against staphylococcus aureus ("Staph aureus"). Exebacase has the potential to be the first-in-class of a new treatment for patients with Staph aureus bacteremia.
Lead Product(s): Exebacase
Therapeutic Area: Infections and Infectious Diseases Product Name: CF-301
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 03, 2023
Details:
CF-301 (exebacase) is a lysin and member of a new class of targeted protein-based antimicrobials that has demonstrated activity against S. aureus in laboratory (in vitro) and animal studies, alone and in addition to conventional antibiotics.
Lead Product(s): Exebacase
Therapeutic Area: Infections and Infectious Diseases Product Name: CF-301
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2022
Details:
CF-301 (exebacase) is a lysin and member of a new class of targeted protein-based antimicrobials that has demonstrated activity against S. aureus in laboratory (in vitro) and animal studies, alone and in addition to conventional antibiotics.
Lead Product(s): Exebacase
Therapeutic Area: Infections and Infectious Diseases Product Name: CF-301
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Maxim Group
Deal Size: $7.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 13, 2022
Details:
The Phase 1b/2 study of exebacase is a randomized, double-blind, placebo-controlled study to assess the efficacy and safety of exebacase in the setting of an arthroscopic DAIR procedure in patients with chronic PJI of the knee due t o S. aureus and/or CoNS.
Lead Product(s): Exebacase
Therapeutic Area: Infections and Infectious Diseases Product Name: CF-301
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 28, 2022
Details:
Company’s lysins, exebacase and CF-296, as additional agents in the treatment armamentarium against bone and joint infections due to their in vitro activity against coagulase-negative staphylococci, and their potential for both local and systemic anti-biofilm activity.
Lead Product(s): CF-296
Therapeutic Area: Infections and Infectious Diseases Product Name: CF-296
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2022
Details:
The positive clinical data demonstrated in these patients underpins the potential to prosecute CF-301 (exebacase) in a blinded clinical study of patients with chronic or recurrent prosthetic joint infections caused by MRSA or coagulase-negative Staph.
Lead Product(s): Exebacase
Therapeutic Area: Infections and Infectious Diseases Product Name: CF-301
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
